MTOR and pericardial effusion: However, the EVERHEART study reported that the initiation of mTOR inhibitors immediately (≤144 h post-HTx) post-transplantation is associated with a poor safety profile, driven primarily by a higher rate of pericardial effusions compared with delayed (4–6 weeks post-transplantation) mTOR inhibitor treatment initiation [13].